Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC ... and lutetium 177 vipivotide tetraxetan (177 Lu-PSMA-617) for patients with prostate-specific membrane ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

Data from 611 FDG PET/CT scans of patients with lung cancer, melanoma, lymphoma, head and neck cancer, and breast cancer, as well as 408 PSMA PET/CT scans of prostate cancer patients, were ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

“This detailed imaging allows for the detection of tiny nodules and is especially useful for diagnosing lung cancer at its most treatable stage,” he explains. On when should a patient get a ...

If you are tested for PSMA, doctors will administer a radioactive dye that binds to these antigens. Under a PET-CT scan, the dye lights up illuminating any trace of prostate cancer cells inside.

PSMA-PET is a diagnostic technology demonstrated to detect advanced ... Prostate cancer was also the second most common cause of cancer death in men (after lung cancer), with approximately 20,000 men ...

Illuccix® is the first and only PSMA-PET [1] prostate cancer imaging agent to receive full regulatory approval in Brazil. Illuccix®, after radiolabeling with 68 Ga, is a radioactive diagnostic agent ...